Aims: To estimate polygenic and polygene x environment contributions to alcohol consumption and problems in the context of childhood maltreatment and lifetime trauma. Design: Main and interaction effects models predicting alcohol consumption and problems were estimated using multiple linear regression. Covariates included age, sex, education, employment status, and ancestral principal components. Setting: USA Participants: A sample of 2,114 Black adults (75% female; Mage=39.88, SD=13.92) recruited from the Grady Trauma Hospital in Atlanta, Georgia. Measurement: Polygenic scores (PGS) for trauma-related symptoms (re-experiencing: PGSREEX, avoidance: PGSAVOID, hyperarousal: PGSHYPER, PTSD symptom score: PGSPCL) and alcohol consumption (PGSAUDIT-C) and use disorder (AUD; PGSAUD) were derived using genome-wide association Million Veterans Program summary statistics with PRS-CS. Findings: Childhood maltreatment and lifetime trauma (excluding childhood abuse) were positively associated with alcohol consumption (AUDIT-C) (βchildhood-maltreatment=0.17, SE=0.02; βlifetime-trauma=0.28, SE=0.02) and alcohol problems (AUDIT-P) (βchildhood-maltreatment=0.25, SE=0.02; βlifetime-trauma=0.27, SE=0.02). None of the PGSs were associated with AUDIT-C, but both the PGSs for re-experiencing (β=0.1, SE=0.03) and avoidance (β=0.08, SE=0.03) were positively associated with AUDIT-P. Experiencing lifetime trauma and being at elevated genetic risk for AUD (interaction-βTrauma_x_PGSAUD=0.17, SE=0.05) and hyperarousal (interaction-βTraumaxPGSHYPER=0.11, SE=0.06) were associated with higher AUDIT-P scores; while more lifetime trauma and higher genetic risk for AUD were associated with higher AUDIT-C scores (interaction-βTrauma_x_PGSAUD=0.12, SE=0.05). Conclusions: Individuals with elevated genetic risk for AUD are more likely to consume alcohol and to develop worse alcohol problems in the context of lifetime trauma. Interventions focused on also minimizing the effects of trauma-exposure would be particularly beneficial among individuals at risk for AUD.

The authors have declared no competing interest.

This work was supported by grants from the National Institute of Health: R01DA042742, K23AT009713, and MH071537.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Emory University gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors.